Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02171221 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Oral DFP-11207 in Solid Tumors
A Phase 1 study, sponsored by Delta-Fly Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02171221 is a Phase 1 study that has completed, run by Delta-Fly Pharma. The registered enrollment target is 23 participants.
The verdict
NCT02171221, a Phase 1 study, has completed, sponsored by Delta-Fly Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
Interventions
- DRUG Oral DFP-11207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02171221
The ClinicalTrials.gov registry entry for NCT02171221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delta-Fly Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral DFP-11207 is the first listed.
NCT02171221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02171221 about?
NCT02171221 is a clinical study titled "Phase I Study of Oral DFP-11207 in Solid Tumors". This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.
What is the current status of trial NCT02171221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-06. Estimated completion is 2018-09-13.
What interventions are being tested in trial NCT02171221?
The interventions under investigation include: Oral DFP-11207 (DRUG).
Who is sponsoring clinical trial NCT02171221?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.